Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7459479 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL9144175 | 0.87 | ALDH1A1 (0.67) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL10255967 | 0.87 | ALDH1A1 (0.67) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL1710890 | 0.85 | ALDH1A1 (0.65) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL12415404 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2HTTL3MBTL1KMT2APOLB | |
| SCHEMBL24072995 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2HTTL3MBTL1KMT2APOLB | |
| SCHEMBL12415402 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL20676018 | 0.80 | SMN1; SMN2 (0.85) | SMN1; SMN2HTTL3MBTL1POLBALDH1A1 | |
| SCHEMBL24322683 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL10905416 | 0.78 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTL3MBTL1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | SMN1; SMN2 365/4885HTT 1972/4885L3MBTL1 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.